• Natya Raghavan, Katherine Webb, Naparat Amornputtisathaporn, and Denis E O'Donnell.
• Respiratory Investigation Unit, Department of Medicine, Queen's University and Kingston General Hospital, Kingston, ON, Canada.
• Curr Opin Pharmacol. 2011 Jun 1; 11 (3): 204-10.

AbstractDyspnea is the most distressing symptom experienced by those suffering from advanced stages of chronic obstructive pulmonary disease (COPD). Activity-related dyspnea in COPD is multifactorial but is associated with increased central neural drive, impaired dynamic respiratory mechanics and abnormal respiratory muscle function. Each of these components can potentially be targeted for pharmacotherapy. Recent advances in the pharmacotherapy of COPD include the development of new long-acting bronchodilators which, when combined, provide sustained improvements in dyspnea. Additionally, novel applications of older therapies such as opiates, furosemide, helium-oxygen, and statins show early promise as dyspnea-relieving interventions in COPD. Effective pharmacological manipulation of the affective dimension of dyspnea remains an important challenge. In this review of the recent literature in this field, we highlight the main advances that have been achieved.Copyright © 2011 Elsevier Ltd. All rights reserved.

12 keywords...

hide…